Abstract

TransMedics Group, Inc. will report fiscal second-quarter 2026 results on August 04, 2026 Post Market, and this preview consolidates the latest quarterly forecasts, last quarter’s actuals, and recent institutional commentary to frame the key debate heading into the print.

Market Forecast

Consensus for the current quarter points to revenue of 183.36 million US dollars, up 24.01% year over year, EBIT of 26.51 million US dollars with 47.78% estimated growth, and EPS of 0.46 with 2.69% growth; the model-implied backdrop suggests continued operating leverage although headline EPS growth is modest relative to revenue expansion. The company’s gross margin, last reported at 58.16%, provides a high-margin base; net profit margin last quarter was 4.21%, and the current-quarter net profitability trend will be shaped by mix and operating expense cadence. The business highlight remains scaling utilization of organ care platforms across liver, heart, and lung, with the liver system as the core driver; the most promising segment is the liver care system with 138.98 million US dollars of last quarter revenue and a rising share of mix, supported by strong procedural growth.

Last Quarter Review

TransMedics Group, Inc. delivered revenue of 173.93 million US dollars, a gross margin of 58.16%, GAAP net income attributable to shareholders of 7.32 million US dollars, a net margin of 4.21%, and adjusted EPS of 0.30; revenue grew 21.18% year over year while EPS declined 57.14% year over year. Management executed against robust procedure growth and mix normalization across organ platforms, with quarter-on-quarter net income growth down 93.06% reflecting investment and timing dynamics. Main business highlights: liver care system revenue was 138.98 million US dollars, heart care system revenue was 30.87 million US dollars, and lung care system revenue was 2.82 million US dollars, underscoring the dominance of liver volumes within the portfolio.

Current Quarter Outlook

Main business momentum

Revenue is projected to rise to 183.36 million US dollars, implying sustained high-teens to mid-twenties growth on expanding adoption of the organ care platforms. The gross margin framework starting from 58.16% last quarter indicates room for positive mix and scale effects as utilization increases, though near-term product and service mix could moderate incremental gains. Operating expense investments in commercial coverage, logistics, and clinical infrastructure may limit near-term net margin expansion, producing EPS growth that lags revenue growth.

Most promising business

The liver care system remains the largest contributor with last quarter revenue of 138.98 million US dollars and a leading share of group sales, supported by growing center adoption and throughput per center. With continued expansion in indications and broader hospital penetration, this franchise is positioned to support revenue outperformance relative to the aggregate platform. The key watch items are procedure volumes, consumables pull-through, and any updates on capacity and supply chain stability that could influence conversion of gross demand into reported revenue.

Key stock price drivers this quarter

Share performance around the print is likely to hinge on revenue trajectory versus the 183.36 million US dollars benchmark and the degree of operating leverage evident in EBIT, estimated at 26.51 million US dollars. Investors will monitor gross margin relative to the 58.16% prior reading for signs of mix and productivity trends, as well as adjusted EPS versus the 0.46 estimate to gauge the balance between growth and investment. Commentary on procedure growth cadence across liver, heart, and lung, and any guidance updates for the second half, could recalibrate expectations for market share gains and profitability convergence.

Analyst Opinions

The balance of recent institutional commentary skews bullish, emphasizing continued revenue growth, sustained high gross margin, and scaling EBIT as adoption of organ care platforms broadens. Analysts highlight the liver care system as the principal driver of upside potential while acknowledging that EPS growth may trail revenue due to ongoing investment in commercial and clinical infrastructure. The bullish view anticipates revenue in line to slightly above the 183.36 million US dollars consensus and EBIT trending toward the 26.51 million US dollars estimate, with upside contingent on procedure volume strength and stable gross margin. The constructive stance expects that a solid delivery on revenue and EBIT can offset near-term EPS variability and reinforce confidence in durable mid-term growth.